OBJECTIVE: Various devices have been proposed for ring stabilization in patients with mitral valve disease. This study reports the intermediate-term results of mitral valve repair with a new semirigid partial annuloplasty ring in a large series of patients. METHODS: A total of 437 consecutive patients were analyzed who underwent mitral valve reconstruction with annuloplasty using the Colvin-Galloway Future band at the German Heart Center in Munich between 2001 and 2005. A total of 237 patients (54.2%) underwent isolated mitral valve repair, and 200 patients (45.8%) underwent a combined procedure. The follow-up is 97% complete (mean follow-up of 405 survivors 2.1 +/- 1.1 years). RESULTS: Overall 30-day mortality was 2.7%. Twenty patients (4.6%) died later after an average of 1.1 +/- 1.1 years. Actuarial survival at 4 years after isolated mitral valve reconstruction and combined procedures was 91% +/- 4% and 87% +/- 2.5%, respectively (P < .001). Twelve patients (2.7%) required a mitral valve reoperation after an average of 4.5 +/- 4.3 months. Five of these reoperations were required for band dehiscence, and 1 reoperation was required for band fracture. Freedom from reoperation at 4 years was 97% +/- 0.9%. At the latest follow-up, 93.5% of the patients showed trivial or mild mitral valve regurgitation, and 86.4% of the patients showed New York Heart Association functional class I or II. CONCLUSION: Mitral valve annuloplasty with the Colvin-Galloway Future band can be performed with a low early and late mortality and an excellent functional outcome. The low incidence of reoperation demonstrates that the Colvin-Galloway Future band is a safe and effective device. The importance of secure anchoring of the device in the mitral annulus has to be emphasized to prevent band dehiscence.
OBJECTIVE: Various devices have been proposed for ring stabilization in patients with mitral valve disease. This study reports the intermediate-term results of mitral valve repair with a new semirigid partial annuloplasty ring in a large series of patients. METHODS: A total of 437 consecutive patients were analyzed who underwent mitral valve reconstruction with annuloplasty using the Colvin-Galloway Future band at the German Heart Center in Munich between 2001 and 2005. A total of 237 patients (54.2%) underwent isolated mitral valve repair, and 200 patients (45.8%) underwent a combined procedure. The follow-up is 97% complete (mean follow-up of 405 survivors 2.1 +/- 1.1 years). RESULTS: Overall 30-day mortality was 2.7%. Twenty patients (4.6%) died later after an average of 1.1 +/- 1.1 years. Actuarial survival at 4 years after isolated mitral valve reconstruction and combined procedures was 91% +/- 4% and 87% +/- 2.5%, respectively (P < .001). Twelve patients (2.7%) required a mitral valve reoperation after an average of 4.5 +/- 4.3 months. Five of these reoperations were required for band dehiscence, and 1 reoperation was required for band fracture. Freedom from reoperation at 4 years was 97% +/- 0.9%. At the latest follow-up, 93.5% of the patients showed trivial or mild mitral valve regurgitation, and 86.4% of the patients showed New York Heart Association functional class I or II. CONCLUSION:Mitral valve annuloplasty with the Colvin-Galloway Future band can be performed with a low early and late mortality and an excellent functional outcome. The low incidence of reoperation demonstrates that the Colvin-Galloway Future band is a safe and effective device. The importance of secure anchoring of the device in the mitral annulus has to be emphasized to prevent band dehiscence.
Authors: Khurram Owais; Han Kim; Kamal R Khabbaz; Remco Bergman; Robina Matyal; Robert C Gorman; Joseph H Gorman; Philip E Hess; Feroze Mahmood Journal: Ann Thorac Surg Date: 2014-03-06 Impact factor: 4.330